At Jazz, our purpose is to innovate to transform the lives of patients and their families. In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36th annual meeting of the Associated Professional Sleep Societies.
We celebrated International Women’s Day and Women’s History Month with awareness-building events and engaging sessions with our Jazz Association of Women Supporters (JAWs) employee-led Affinity Forum, including a very special event for our employees featuring Brooke Baldwin, award-winning journalist and author of the book, Huddle: How Women Unlock Their Collective Power. After hearing from Brooke and having a rich dialogue, we closed out our Women’s History Month event with the announcement of distinguished recognition for two of our Jazz colleagues by the Healthcare Businesswomen’s Association (HBA) as 2022 honorees in the healthcare industry.
At Jazz, we push ourselves and other stakeholders to think holistically about patients’ health to minimize the risk of patient co-morbidities and address significant unmet needs. To learn more about the often-overlooked co-morbidities associated with narcolepsy and the progress Jazz has made to address them, Jazz’s Dr. Todd Kirby spoke with sleep specialist Dr. Richard K. Bogan.
At this year’s virtual J.P. Morgan Healthcare Conference, we presented key achievements and announced Vision 2025 to deliver sustainable growth and enhanced value. Guided by our patient-centric approach, Jazz is committed to taking bold steps to deliver life-changing therapies that create new or better standards of care.
At Jazz Pharmaceuticals, we’re committed to developing life-changing medicines for people affected by serious diseases for which current therapies are lacking. This begins with talking to those living with disease and reflecting their needs in our R&D priorities and throughout all stages of our drug development process as we pursue novel, meaningful medicines that advance patient care.
Bruce Cozadd, our Chief Executive Officer, looks back on Jazz’s major achievements of 2021 amid ongoing challenges of the pandemic, reflecting on the significant strides made for patient populations, and reinstating Jazz’s continued commitment to developing breakthrough therapeutics as we kick off 2022.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.